Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/29/18
End: 12/31/19
Due: 12/31/20
Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.
Phase: N/A
Priority: Normal
Start: 07/14/16
End: 07/31/18
Due: 07/31/19
Phase: N/A
Priority: Normal
Start: 06/30/16
End: 06/27/22
Due: 06/27/23
Phase: N/A
Priority: Normal
Start: 07/05/22
End: 08/22/23
Due: 08/22/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System | NCT03427450 | Angle plc | user2@example.com | None | 2018-03-29 | 2019-12-31 | 2020-12-31 | - | - | 2025-07-14 |
| Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass. | NCT02785731 | Angle plc | user2@example.com | None | 2016-07-14 | 2018-07-31 | 2019-07-31 | - | - | 2025-07-14 |
| Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass. | NCT02781272 | Angle plc | user2@example.com | None | 2016-06-30 | 2022-06-27 | 2023-06-27 | - | - | 2025-07-14 |
| Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System | NCT05437679 | Angle plc | user2@example.com | None | 2022-07-05 | 2023-08-22 | 2024-08-22 | - | - | 2025-07-14 |